Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review evaluates PSMA-targeted therapies in metastatic castration-resistant prostate cancer, highlighting efficacy and nephrotoxicity risks.

Lutetium-177 therapy shows promise, recently approved for PSMA-positive metastatic castration-resistant prostate cancer, with ongoing trials.
Recent advancements reveal a survival benefit in patients undergoing PSMA-targeted radionuclide therapy for mCRPC, warranting further exploration.
Assessment of biomarkers for therapeutic response is crucial as clinical trials examine both mono- and combination therapies.
Limitations exist due to nephrotoxicity risks associated with long-term PSMA-targeted therapy, emphasizing caution in treatment application.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Review evaluates PSMA-targeted therapies in metastatic castration-resistant prostate cancer, highlighting efficacy and nephrotoxicity risks.